Evidence map›Paper›PMID 38344144›Full record

ArticleFrontiers in oncology2023

Development and evaluation of INT

Raymond A Isidro, Anu Chittenden, McKenzie Walker, Alison Schwartz, Diane R Koeller, Connor P Hayes, Busra Unal, Monica Devi Manam, Ryan M Buehler, Danielle K Manning and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Raymond A Isidro *Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Anu Chittenden *Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, United States.
McKenzie Walker *Division of Genetics, Brigham and Women's Hospital, Boston, MA, United States.
Alison SchwartzDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, United States.
Diane R KoellerDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, United States.
Connor P HayesDivision of Genetics, Brigham and Women's Hospital, Boston, MA, United States.
Busra UnalDivision of Genetics, Brigham and Women's Hospital, Boston, MA, United States.
Monica Devi ManamDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Ryan M BuehlerDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, United States.
Danielle K ManningDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Mark S RedstonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Matthew B YurgelunHarvard Medical School, Boston, MA, United States.
Huma Q RanaHarvard Medical School, Boston, MA, United States.
Judy E GarberHarvard Medical School, Boston, MA, United States.
Arezou A GhazaniDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USCancer Genetics (United States) · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of variants of uncertain significance (VUS) in DNA mismatch repair (MMR) genes leads to uncertainty in the clinical management of patients being evaluated for Lynch syndrome (LS). Currently, there is no platform to systematically use tumor-derived evidence alongside germline data for the assessment of VUS in relation to LS. We developed INT

Indexed as

germline VUSINT2GRATELynch syndromesomatic and germline integrationtumor signature profile

Identifiers

PMID38344144
PMCPMC10854004
OpenAlexW4391256698

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.